AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
oxytocin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| oxytocin derivatives | 2042 | 50-56-6 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
A nonapeptide hormone released from the neurohypophysis (PITUITARY GLAND, POSTERIOR). It differs from VASOPRESSIN by two amino acids at residues 3 and 8. Oxytocin acts on SMOOTH MUSCLE CELLS, such as causing UTERINE CONTRACTIONS and MILK EJECTION.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 15 | U | N |
| 200 | U | O |
| 15 | U | P |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| S (Water solubility) | 12 mg/mL | Bocci G, Oprea TI, Benet LZ |
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 1 | Bocci G, Oprea TI, Benet LZ |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| kinase-safety-class | ACVR2B,CDK5,EIF2AK3,GRK2,PDK1,PDK2,PDK4,PRKDC | 8 | |||
| kinase-selectivity-class | GRK2,PDK1 | 2 | |||
| mdck-mdr1-bcrp-efflux | MDCK-MDR1-BCRP efflux ratio | 1.429 | Moderate | 0.66 | |
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| April 17, 1980 | FDA | NOVARTIS |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Exposure during pregnancy | 904.66 | 34.70 | 405 | 6112 | 238005 | 90383925 |
| Maternal exposure during pregnancy | 706.84 | 34.70 | 391 | 6126 | 359672 | 90262258 |
| Maternal exposure during delivery | 579.77 | 34.70 | 115 | 6402 | 3731 | 90618199 |
| Postpartum haemorrhage | 511.68 | 34.70 | 96 | 6421 | 2305 | 90619625 |
| Premature delivery | 381.30 | 34.70 | 132 | 6385 | 38630 | 90583300 |
| Uterine atony | 255.22 | 34.70 | 40 | 6477 | 308 | 90621622 |
| Hypotension | 216.69 | 34.70 | 182 | 6335 | 325215 | 90296715 |
| Caesarean section | 208.82 | 34.70 | 70 | 6447 | 18507 | 90603423 |
| Drug ineffective | 194.56 | 34.70 | 350 | 6167 | 1383948 | 89237982 |
| Normal newborn | 170.95 | 34.70 | 64 | 6453 | 23298 | 90598632 |
| Uterine rupture | 158.30 | 34.70 | 32 | 6485 | 1137 | 90620793 |
| Foetal exposure during pregnancy | 154.99 | 34.70 | 71 | 6446 | 42904 | 90579026 |
| Premature baby | 124.80 | 34.70 | 52 | 6465 | 25025 | 90596905 |
| Ventilation perfusion mismatch | 121.80 | 34.70 | 23 | 6494 | 569 | 90621361 |
| Pre-eclampsia | 113.76 | 34.70 | 39 | 6478 | 11009 | 90610921 |
| Low birth weight baby | 103.67 | 34.70 | 35 | 6482 | 9432 | 90612498 |
| Anaphylactoid syndrome of pregnancy | 88.43 | 34.70 | 13 | 6504 | 61 | 90621869 |
| Electrocardiogram ST segment depression | 87.06 | 34.70 | 24 | 6493 | 3279 | 90618651 |
| Anaphylactic reaction | 79.55 | 34.70 | 59 | 6458 | 87465 | 90534465 |
| Bradycardia foetal | 79.31 | 34.70 | 16 | 6501 | 562 | 90621368 |
| Tachycardia | 74.58 | 34.70 | 73 | 6444 | 157600 | 90464330 |
| Placenta accreta | 73.09 | 34.70 | 13 | 6504 | 228 | 90621702 |
| Amniotic cavity infection | 70.37 | 34.70 | 17 | 6500 | 1379 | 90620551 |
| Uterine haemorrhage | 70.00 | 34.70 | 22 | 6495 | 4730 | 90617200 |
| Small for dates baby | 68.87 | 34.70 | 22 | 6495 | 4985 | 90616945 |
| Hypoxia | 68.47 | 34.70 | 50 | 6467 | 72349 | 90549581 |
| Failed induction of labour | 64.24 | 34.70 | 13 | 6504 | 464 | 90621466 |
| Uterine hypertonus | 63.08 | 34.70 | 12 | 6505 | 309 | 90621621 |
| Premature rupture of membranes | 62.63 | 34.70 | 21 | 6496 | 5537 | 90616393 |
| Acute pulmonary oedema | 61.95 | 34.70 | 24 | 6493 | 9556 | 90612374 |
| Foetal exposure during delivery | 61.06 | 34.70 | 12 | 6505 | 368 | 90621562 |
| Stillbirth | 60.33 | 34.70 | 22 | 6495 | 7421 | 90614509 |
| Foetal anaemia | 58.89 | 34.70 | 10 | 6507 | 132 | 90621798 |
| Disseminated intravascular coagulation | 57.57 | 34.70 | 29 | 6488 | 21509 | 90600421 |
| Endometritis | 57.35 | 34.70 | 14 | 6503 | 1186 | 90620744 |
| Uterine tachysystole | 57.24 | 34.70 | 8 | 6509 | 24 | 90621906 |
| Pulmonary oedema | 56.72 | 34.70 | 42 | 6475 | 62038 | 90559892 |
| Pericoronitis | 52.78 | 34.70 | 9 | 6508 | 122 | 90621808 |
| Maternal exposure during breast feeding | 52.71 | 34.70 | 19 | 6498 | 6201 | 90615729 |
| Fatigue | 52.24 | 34.70 | 10 | 6507 | 1154013 | 89467917 |
| Intermittent positive pressure breathing | 51.21 | 34.70 | 8 | 6509 | 60 | 90621870 |
| Retained placenta or membranes | 50.29 | 34.70 | 10 | 6507 | 326 | 90621604 |
| Delivery | 47.12 | 34.70 | 13 | 6504 | 1780 | 90620150 |
| Foetal death | 47.03 | 34.70 | 25 | 6492 | 20698 | 90601232 |
| Gestational diabetes | 46.17 | 34.70 | 20 | 6497 | 10562 | 90611368 |
| Live birth | 45.77 | 34.70 | 41 | 6476 | 79066 | 90542864 |
| Vascular resistance systemic decreased | 45.27 | 34.70 | 8 | 6509 | 135 | 90621795 |
| Hypothermia | 44.66 | 34.70 | 22 | 6495 | 15553 | 90606377 |
| Mean arterial pressure decreased | 41.90 | 34.70 | 8 | 6509 | 210 | 90621720 |
| Foetal growth restriction | 41.81 | 34.70 | 18 | 6499 | 9362 | 90612568 |
| Premature labour | 41.68 | 34.70 | 20 | 6497 | 13356 | 90608574 |
| Periventricular leukomalacia | 41.44 | 34.70 | 8 | 6509 | 223 | 90621707 |
| Vaginal haemorrhage | 39.93 | 34.70 | 26 | 6491 | 31245 | 90590685 |
| Polyhydramnios | 38.56 | 34.70 | 12 | 6505 | 2496 | 90619434 |
| Foetal heart rate deceleration abnormality | 38.01 | 34.70 | 9 | 6508 | 670 | 90621260 |
| Uterine hypotonus | 37.89 | 34.70 | 7 | 6510 | 153 | 90621777 |
| Gestational hypertension | 36.21 | 34.70 | 12 | 6505 | 3050 | 90618880 |
| Stroke volume increased | 35.53 | 34.70 | 5 | 6512 | 16 | 90621914 |
| Haemodynamic instability | 34.91 | 34.70 | 17 | 6500 | 11722 | 90610208 |
| Cardiac output increased | 34.71 | 34.70 | 8 | 6509 | 529 | 90621401 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Foetal exposure during pregnancy | 469.78 | 112.34 | 109 | 434 | 47202 | 42573590 |
| Premature baby | 230.38 | 112.34 | 54 | 489 | 23099 | 42597693 |
| Low birth weight baby | 134.95 | 112.34 | 30 | 513 | 9925 | 42610867 |
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Exposure during pregnancy | 839.34 | 32.25 | 313 | 5183 | 167111 | 110416692 |
| Maternal exposure during pregnancy | 821.38 | 32.25 | 346 | 5150 | 254537 | 110329266 |
| Maternal exposure during delivery | 572.98 | 32.25 | 106 | 5390 | 3459 | 110580344 |
| Postpartum haemorrhage | 480.84 | 32.25 | 83 | 5413 | 1806 | 110581997 |
| Premature delivery | 389.39 | 32.25 | 116 | 5380 | 30516 | 110553287 |
| Uterine atony | 255.98 | 32.25 | 37 | 5459 | 235 | 110583568 |
| Caesarean section | 200.30 | 32.25 | 58 | 5438 | 13759 | 110570044 |
| Normal newborn | 190.07 | 32.25 | 62 | 5434 | 21834 | 110561969 |
| Drug ineffective | 149.00 | 32.25 | 267 | 5229 | 1520273 | 109063530 |
| Pre-eclampsia | 137.37 | 32.25 | 39 | 5457 | 8611 | 110575192 |
| Uterine rupture | 130.04 | 32.25 | 24 | 5472 | 767 | 110583036 |
| Ventilation perfusion mismatch | 123.46 | 32.25 | 23 | 5473 | 774 | 110583029 |
| Anaphylactoid syndrome of pregnancy | 94.14 | 32.25 | 13 | 5483 | 56 | 110583747 |
| Hypotension | 84.10 | 32.25 | 116 | 5380 | 523733 | 110060070 |
| Electrocardiogram ST segment depression | 83.90 | 32.25 | 24 | 5472 | 5437 | 110578366 |
| Uterine haemorrhage | 79.91 | 32.25 | 21 | 5475 | 3473 | 110580330 |
| Amniotic cavity infection | 78.02 | 32.25 | 16 | 5480 | 891 | 110582912 |
| Premature rupture of membranes | 74.03 | 32.25 | 21 | 5475 | 4616 | 110579187 |
| Tachycardia | 73.17 | 32.25 | 72 | 5424 | 226573 | 110357230 |
| Stillbirth | 71.19 | 32.25 | 20 | 5476 | 4244 | 110579559 |
| Endometritis | 65.41 | 32.25 | 14 | 5482 | 960 | 110582843 |
| Placenta accreta | 64.73 | 32.25 | 11 | 5485 | 216 | 110583587 |
| Bradycardia foetal | 63.01 | 32.25 | 10 | 5486 | 126 | 110583677 |
| Failed induction of labour | 61.20 | 32.25 | 11 | 5485 | 302 | 110583501 |
| Anaphylactic reaction | 58.15 | 32.25 | 47 | 5449 | 114253 | 110469550 |
| Acute pulmonary oedema | 57.22 | 32.25 | 24 | 5472 | 16972 | 110566831 |
| Hypoxia | 57.06 | 32.25 | 49 | 5447 | 129466 | 110454337 |
| Retained placenta or membranes | 56.38 | 32.25 | 10 | 5486 | 254 | 110583549 |
| Gestational diabetes | 56.38 | 32.25 | 19 | 5477 | 7370 | 110576433 |
| Foetal death | 55.17 | 32.25 | 23 | 5473 | 16022 | 110567781 |
| Pericoronitis | 53.81 | 32.25 | 9 | 5487 | 160 | 110583643 |
| Maternal exposure during breast feeding | 53.52 | 32.25 | 16 | 5480 | 4222 | 110579581 |
| Disseminated intravascular coagulation | 49.93 | 32.25 | 29 | 5467 | 41257 | 110542546 |
| Uterine hypertonus | 48.95 | 32.25 | 9 | 5487 | 281 | 110583522 |
| Premature labour | 48.65 | 32.25 | 18 | 5478 | 9154 | 110574649 |
| Delivery | 48.45 | 32.25 | 11 | 5485 | 990 | 110582813 |
| Vaginal haemorrhage | 48.29 | 32.25 | 24 | 5472 | 25050 | 110558753 |
| Live birth | 47.30 | 32.25 | 34 | 5462 | 69450 | 110514353 |
| Pulmonary oedema | 46.20 | 32.25 | 39 | 5457 | 100620 | 110483183 |
| Polyhydramnios | 46.04 | 32.25 | 12 | 5484 | 1921 | 110581882 |
| Vascular resistance systemic decreased | 43.26 | 32.25 | 8 | 5488 | 258 | 110583545 |
| Small for dates baby | 41.54 | 32.25 | 9 | 5487 | 653 | 110583150 |
| Uterine hypotonus | 40.88 | 32.25 | 7 | 5489 | 144 | 110583659 |
| Gestational hypertension | 39.68 | 32.25 | 11 | 5485 | 2223 | 110581580 |
| Mean arterial pressure decreased | 38.37 | 32.25 | 8 | 5488 | 483 | 110583320 |
| Stroke volume increased | 37.14 | 32.25 | 5 | 5491 | 17 | 110583786 |
| Cardiac output increased | 36.63 | 32.25 | 8 | 5488 | 603 | 110583200 |
| Hypothermia | 35.90 | 32.25 | 20 | 5476 | 26282 | 110557521 |
| Premature baby | 35.13 | 32.25 | 12 | 5484 | 4843 | 110578960 |
| Fatigue | 34.53 | 32.25 | 9 | 5487 | 1215949 | 109367854 |
| Premature separation of placenta | 33.76 | 32.25 | 9 | 5487 | 1571 | 110582232 |
| Uterine inversion | 33.40 | 32.25 | 4 | 5492 | 3 | 110583800 |
| Foetal heart rate deceleration abnormality | 33.27 | 32.25 | 6 | 5490 | 168 | 110583635 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | G02AC01 | GENITO URINARY SYSTEM AND SEX HORMONES OTHER GYNECOLOGICALS UTEROTONICS Ergot alkaloids and oxytocin incl. analogues, in combination |
| ATC | H01BB02 | SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES POSTERIOR PITUITARY LOBE HORMONES Oxytocin and analogues |
| FDA CS | M0015703 | Oxytocin |
| FDA PE | N0000009705 | Increased Uterine Smooth Muscle Contraction or Tone |
| MeSH PA | D010120 | Oxytocics |
| MeSH PA | D012102 | Reproductive Control Agents |
| FDA EPC | N0000175828 | Oxytocic |
| CHEBI has role | CHEBI:22587 | antiviral agent |
| CHEBI has role | CHEBI:35469 | antidepressant |
| CHEBI has role | CHEBI:35476 | antipsychotic agent |
| CHEBI has role | CHEBI:35480 | analgesic |
| CHEBI has role | CHEBI:35554 | cardiovascular drug |
| CHEBI has role | CHEBI:35610 | antineoplastic agent |
| CHEBI has role | CHEBI:35620 | vasodilator agent |
| CHEBI has role | CHEBI:36063 | oxytocic |
| CHEBI has role | CHEBI:38070 | anti-arrhythmia drug |
| CHEBI has role | CHEBI:50779 | appetite enhancer |
| CHEBI has role | CHEBI:55324 | gastrointestinal drug |
| CHEBI has role | CHEBI:66980 | nootropic agent |
| CHEBI has role | CHEBI:67079 | anti-inflammatory agent |
| CHEBI has role | CHEBI:74518 | anti-obesity agent |
| CHEBI has role | CHEBI:176497 | geroprotector |
Related Drugs by ATC class:
G02AC Ergot alkaloids and oxytocin incl. analogues, in combination 1 drug
H01BB Oxytocin and analogues 2 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Postpartum hemorrhage | indication | 47821001 | |
| Incomplete miscarriage | indication | 156072005 | |
| Induction of labor | indication | 236958009 | |
| Pregnancy with abortive outcome | indication | 363681007 | |
| Placental Reserve Studies | off-label use | ||
| Multiple pregnancy | contraindication | 16356006 | |
| Grand multipara | contraindication | 18656007 | |
| Placenta previa | contraindication | 36813001 | DOID:11060 |
| Hypertensive disorder | contraindication | 38341003 | DOID:10763 |
| Fetal distress | contraindication | 130955003 | |
| Deliveries by cesarean | contraindication | 200144004 | |
| Finding of malposition of fetus | contraindication | 289365005 |
🐶 Veterinary Drug Use
| Species | Use | Relation |
|---|---|---|
| Cats | Uterine contractor to precipitate and accelerate normal parturition and postpartum evacuation of uterine debris | Indication |
| Cats | Postoperatively following cesarean section to facilitate involution and resistance to the large inflow of blood | Indication |
| Cattle | Uterine contractor to precipitate and accelerate normal parturition and postpartum evacuation of uterine debris | Indication |
| Cattle | Postoperatively following cesarean section to facilitate involution and resistance to the large inflow of blood | Indication |
| Cattle | Contracts smooth muscle cells of the mammary gland for milk letdown | Indication |
| Dogs | Uterine contractor to precipitate and accelerate normal parturition and postpartum evacuation of uterine debris | Indication |
| Dogs | Postoperatively following cesarean section to facilitate involution and resistance to the large inflow of blood | Indication |
| Horses | Uterine contractor to precipitate and accelerate normal parturition and postpartum evacuation of uterine debris | Indication |
| Horses | Postoperatively following cesarean section to facilitate involution and resistance to the large inflow of blood | Indication |
| Sheep | Uterine contractor to precipitate and accelerate normal parturition and postpartum evacuation of uterine debris | Indication |
| Sheep | Postoperatively following cesarean section to facilitate involution and resistance to the large inflow of blood | Indication |
| Swine | Uterine contractor to precipitate and accelerate normal parturition and postpartum evacuation of uterine debris | Indication |
| Swine | Postoperatively following cesarean section to facilitate involution and resistance to the large inflow of blood | Indication |
| Swine | Contracts smooth muscle cells of the mammary gland for milk letdown | Indication |
🐶 Veterinary products
| Product | Applicant | Ingredients |
|---|---|---|
| Oxytocin Injection | Zoetis Inc. | 1 |
| Oxytocin (Label Under Distributors) | Bimeda Animal Health Limited | 1 |
| Oxytocin Injectable | Bimeda Animal Health Limited | 1 |
| PVL Oxytocin Injectable | Bimeda Animal Health Limited | 1 |
| Oxytocin Injection | Bimeda Animal Health Limited | 1 |
| Oxytocin Injection | Bimeda Animal Health Limited | 1 |
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 9.65 | acidic |
| pKa2 | 12.47 | acidic |
| pKa3 | 12.94 | acidic |
| pKa4 | 13.18 | acidic |
| pKa5 | 13.47 | acidic |
| pKa6 | 13.7 | acidic |
| pKa7 | 13.89 | acidic |
| pKa8 | 6.4 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Oxytocin receptor | GPCR | AGONIST | Ki | 9.10 | CHEMBL | CHEMBL | |||
| Vasopressin V1b receptor | GPCR | EC50 | 6.35 | WOMBAT-PK | |||||
| Vasopressin V2 receptor | GPCR | EC50 | 6.10 | WOMBAT-PK | |||||
| Oxytocin-neurophysin 1 | Secreted | WOMBAT-PK | |||||||
| Vasopressin V1a receptor | GPCR | EC50 | 6.91 | WOMBAT-PK | |||||
| Oxytocin receptor | GPCR | Ki | 9.05 | CHEMBL | |||||
| Vasopressin V2 receptor | GPCR | Ki | 7.21 | CHEMBL | |||||
| Vasopressin V1a receptor | GPCR | AGONIST | Ki | 6.10 | IUPHAR |
External reference:
| ID | Source |
|---|---|
| 4018039 | VUID |
| N0000146381 | NUI |
| D00089 | KEGG_DRUG |
| 4018039 | VANDF |
| C0030095 | UMLSCUI |
| CHEBI:7872 | CHEBI |
| CHEMBL395429 | ChEMBL_ID |
| D010121 | MESH_DESCRIPTOR_UI |
| DB00107 | DRUGBANK_ID |
| 2174 | IUPHAR_LIGAND_ID |
| 1480 | INN_ID |
| 1JQS135EYN | UNII |
| 439302 | PUBCHEM_CID |
| 7824 | RXNORM |
| 4537 | MMSL |
| 5223 | MMSL |
| d00584 | MMSL |
| 001307 | NDDF |
| 112115002 | SNOMEDCT_US |
| 12369008 | SNOMEDCT_US |
| 1JQS135EYN | INXIGHT DRUGS |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Oxytocin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0143-9742 | INJECTION | 10 [USPU] | INTRAMUSCULAR | ANDA | 20 sections |
| Oxytocin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0143-9743 | INJECTION | 10 [USPU] | INTRAMUSCULAR | ANDA | 20 sections |
| Oxytocin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0641-6114 | INJECTION | 10 [USPU] | INTRAMUSCULAR | NDA | 20 sections |
| Oxytocin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0641-6115 | INJECTION | 10 [USPU] | INTRAMUSCULAR | NDA | 20 sections |
| Pitocin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42023-116 | INJECTION | 10 [iU] | INTRAVENOUS | NDA | 22 sections |
| Pitocin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42023-116 | INJECTION | 10 [iU] | INTRAVENOUS | NDA | 22 sections |
| Pitocin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42023-116 | INJECTION | 10 [iU] | INTRAVENOUS | NDA | 22 sections |
| Pitocin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42023-130 | INJECTION | 10 [iU] | INTRAVENOUS | NDA | 22 sections |
| Oxytocin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 52533-048 | INJECTION, SOLUTION | 10 [USPU] | INTRAVENOUS | unapproved drug other | 1 sections |
| Oxytocin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 52533-051 | INJECTION, SOLUTION | 2 [USPU] | INTRAVENOUS | unapproved drug other | |
| Oxytocin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 52533-054 | INJECTION, SOLUTION | 30 [USPU] | INTRAVENOUS | unapproved drug other | |
| Oxytocin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 52533-055 | INJECTION, SOLUTION | 30 [USPU] | INTRAVENOUS | unapproved drug other | |
| Oxytocin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 52533-056 | INJECTION, SOLUTION | 15 [USPU] | INTRAVENOUS | unapproved drug other | 1 sections |
| Oxytocin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 52533-056 | INJECTION, SOLUTION | 30 [USPU] | INTRAVENOUS | unapproved drug other | 1 sections |
| Oxytocin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 52533-105 | INJECTION, SOLUTION | 2 [USPU] | INTRAVENOUS | unapproved drug other | |
| Oxytocin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 52533-170 | INJECTION, SOLUTION | 30 [USPU] | INTRAVENOUS | unapproved drug other | |
| Oxytocin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 52533-233 | INJECTION, SOLUTION | 20 [USPU] | INTRAVENOUS | unapproved drug other | 1 sections |
| Oxytocin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 52533-234 | INJECTION, SOLUTION | 30 [USPU] | INTRAVENOUS | unapproved drug other | 1 sections |
| Oxytocin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 55154-9584 | INJECTION, SOLUTION | 10 [USPU] | INTRAVENOUS | NDA | 12 sections |
| Oxytocin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63323-012 | INJECTION, SOLUTION | 10 [USPU] | INTRAVENOUS | NDA | 12 sections |
| Oxytocin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63323-012 | INJECTION, SOLUTION | 10 [USPU] | INTRAVENOUS | NDA | 12 sections |
| Oxytocin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 65219-021 | INJECTION, SOLUTION | 10 [USPU] | INTRAVENOUS | NDA | 12 sections |
| Oxytocin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70518-4233 | INJECTION, SOLUTION | 10 [USPU] | INTRAVENOUS | NDA | 12 sections |